药物受理最新动态：GLAXOSMITHKLINE INC.盐酸帕罗西汀肠溶缓释片进口再注册申请获受理

Core Viewpoint - The application for Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets by GlaxoSmithKline Inc. has been accepted by the National Medical Products Administration of China, indicating a significant step in the company's product portfolio expansion in the Chinese market [1] Group 1: Application Details - The application was accepted on February 5, 2026, with the acceptance number JYHZ2600018 [1] - The drug type is classified as a chemical drug, and the application type is for import re-registration [1] - The companies involved in the application include GlaxoSmithKline Inc., Bora Pharmaceutical Services Inc., and GlaxoSmithKline (China) Investment Company Limited [1]